About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker CGTX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Sep 9, 2026A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
NCT05637801 · Alzheimer Disease, Alzheimer Disease 1
Spectris™ AD - Active, Spectris™ AD - Sham
CGTX
Cognito Therapeutics, Inc.
Not applicableCompleted673Jun 22, 2026Registry ↗
Aug 10, 2026A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656 · Early Alzheimer's Disease
CT1812, Placebo
CGTX
Cognition Therapeutics
Phase 2Active, not recruiting540May 31, 2027Registry ↗
May 28, 2026Expanded Access Program for CT1812 (Zervimesine)
NCT06961760 · Dementia With Lewy Bodies
zervimesine
CGTX
Cognition Therapeutics
—No longer available——Registry ↗
Mar 12, 2026Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate…
NCT05225415 · Dementia With Lewy Bodies
CT1812
CGTX
Cognition Therapeutics
Phase 2Completed130Nov 25, 2024Registry ↗
Aug 11, 2025A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's…
NCT03507790 · Mild to Moderate Alzheimer's Disease
CT1812, Placebo
CGTX
Cognition Therapeutics
Phase 2Completed153May 29, 2024Registry ↗
Apr 16, 2025Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (G…
NCT05893537 · Age-Related Macular Degeneration
Active Comparator CT1812, Placebo Comparator
CGTX
Cognition Therapeutics
Phase 2Terminated100Mar 4, 2025Registry ↗
Nov 29, 2024Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
NCT04735536 · Alzheimer Disease
CT1812, Placebo
CGTX
Cognition Therapeutics
Phase 2Completed16Apr 26, 2023Registry ↗
May 7, 2024Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
NCT06245031 · Alzheimer Disease, Cognitive Impairment
Sensory Stimulation System (GS120) - Active
CGTX
Cognito Therapeutics, Inc.
Not applicableEnrolling by invitation402Dec 2026Registry ↗
Sep 7, 2023Effect of CT1812 Treatment on Brain Synaptic Density
NCT03493282 · Alzheimer Disease
Active Treatment- CT1812 100 mg, Active Treatment- CT1812 3…
CGTX
Cognition Therapeutics
Phase 1/2Completed43Oct 16, 2020Registry ↗
Jul 21, 2023Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult…
NCT05225389 · Alzheimer Disease
300 mg [C14] CT1812
CGTX
Cognition Therapeutics
Phase 1Completed8Jan 17, 2022Registry ↗
Apr 12, 2023Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
NCT05248672 · Alzheimer Disease
CT1812
CGTX
Cognition Therapeutics
Phase 1Completed35Jun 1, 2022Registry ↗
Jan 12, 2022Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in…
NCT03522129 · Alzheimer Disease
CT1812, Placebo
CGTX
Cognition Therapeutics
Phase 1Completed3Feb 6, 2019Registry ↗
Aug 24, 2021Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improv…
NCT03661034 · Alzheimer Disease, Early Onset, Alzheimer Disease
GammaSense Stimulation System (non-invasive, non-significan…
CGTX
Cognito Therapeutics, Inc.
Not applicableUnknown20May 1, 2021Registry ↗
Aug 24, 2021Multi-Center Study of Sensory Stimulation to Improve Brain Function
NCT03556280 · Alzheimer Disease, Cognitive Impairment
GammaSense Stimulation System (Active Settings), GammaSense…
CGTX
Cognito Therapeutics, Inc.
Not applicableActive, not recruiting60Aug 1, 2020Registry ↗
Oct 23, 2018Drug Interaction Study of CT1812 in Healthy Volunteers
NCT03716427 · Healthy Volunteers
CT1812, tolbutamide
CGTX
Cognition Therapeutics
Phase 1Completed16Dec 27, 2016Registry ↗
Jul 26, 2018Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
NCT02907567 · Alzheimer's Disease
CT1812, Placebo
CGTX
Cognition Therapeutics
Phase 1/2Completed19Aug 24, 2017Registry ↗
Sep 7, 2016Ascending Dose Study of CT1812 in Healthy Volunteers
NCT02570997 · Cognitive Impairment
CT1812, Placebo
CGTX
Cognition Therapeutics
Phase 1Completed80May 2016Registry ↗

17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:24 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances